tech
March 9, 2026
Europe Accelerates AI Drug Discovery as DeepMind Spinoff Targets Trials This Year
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments.
TL;DR
- Isomorphic Labs, a Google DeepMind spinoff, anticipates starting clinical trials for AI-designed drugs by the end of the year.
- AI algorithms can accelerate drug discovery by analyzing vast datasets to identify promising molecules, potentially reducing development time and costs.
- Over 460 AI startups are active in drug discovery, with a significant portion based in Europe, attracting substantial global investment.
- Collaborations like Isomorphic Labs' deals with Eli Lilly and Novartis, and Exscientia's rapid advancement of an AI-designed drug candidate, demonstrate the practical application of AI in the field.
- Despite AI's potential, challenges remain in physical testing, clinical trials, and regulatory approval processes.
Continue reading the original article